Techno Trends
TechnoTrends provide comprehensive coverage of the innovations and inventions in pharma products and pharma technologies across the world. The up-to-date listing of latest pharmaceutical product news and technology trends in the global pharma industry, keeps you abreast with all the latest pharmaceutical innovations happening world over.
HUTCHMED Introduces First-of-its-Kind Savolitinib for Gastric Cancer Treatment
HUTCHMED has introduced first-of-its-kind savolitinib for the treatment of patients with locally advanced or metastatic gastric cancer or gastroesophageal junction (“GEJ”) adenocarcinoma patients with mesenchymal epithelial transition factor (“MET”) amplification who have failed to responded to at least two standard treatments.
University of Oxford Developed Breakthrough Nanopore Technology for Protein Variant Detection
The University of Oxford has made a significant breakthrough in the field of protein analysis with the development of an innovative nanopore technology.
Polpharma Biologics Discovered First-of-its-Kind Natalizumab Biosimilar
Natalizumab, the biosimilar aims to replicate the characteristics of the reference medication, including its dosage form, route of administration, dosing regimen, and presentation
Revance Therapeutics Introduces First Daxxify® for the Treatment of Cervical Dystonia
Revance Therapeutics has introduced a new treatment option named Daxxify® (DaxibotulinumtoxinA-lanm). This is the first approval for the treatment of cervical dystonia in adults.
Janssen Introduces AKEEGA™ First Dual Action Tablet for BRCA-Positive Metastatic Castration-Resistant Prostate Cancer
Janssen Introduces AKEEGA™ First Dual Action Tablet for BRCA-Positive Metastatic Castration-Resistant Prostate Cancer
Fujifilm Cellular Dynamics Introduces Novel Human iPSC-Derived Blood-Brain Barrier Isogenic Kit
FUJIFILM Cellular Dynamics introduced new human iPSC-derived iCell® blood-brain barrier isogenic kit. This kit is specifically tailored for researchers and scientists working in the field of neuroactive drug exploration.
Fosun Pharma Developed Novel FCN-159 Tablet, a Self-Developed MEK1/2 Inhibitor
Fosun Pharma has developed a groundbreaking MEK1/2 inhibitor known as FCN-159 tablet, with the aim of treating adult patients suffering from inoperable or post-operative residual/recurrent NF1-associated plexiform neurofibromas.
Antengene Developed World’s First XPOVIO® for the Treatment of Relapsed and/or Refractory Multiple Myeloma
Antengene has approved New Drug Application (NDA) for XPOVIO® (selinexor) in combination with dexamethasone for the treatment of relapsed and/or refractory multiple myeloma (R/R MM) patients who have received multiple prior therapies.
Biogen and Sage Therapeutics Introduce First-of-its-Kind ZURZUVAE™ for Postpartum Depression
Biogen has introduced first-of-its-kind ZURZUVAE™ (zuranolone) approved for adults with postpartum depression (PPD). This new treatment seems to be a significant step forward in addressing the needs of women who suffer from this condition.
Jacobio Pharma Introduces Novel KRAS G12C Inhibitor Glecirasib for Pancreatic Cancer
Jacobio Pharma has introduced an innovative in-house solution with the KRAS G12C inhibitor, Glecirasib, aimed at treating patients with pancreatic cancer.
